Cold Agglutinin Disease (CAD): Impact of a Rare Anemia and the Promise of New Therapies

CME: 0.5

Target Audience

The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, internists, oncology nurses, nurse navigators, nurse practitioners, physician assistants, and pharmacists.

Statement of Need/Program Overview

Diagnosis of cold agglutinin disease (CAD) is usually slow, with misdiagnosed symptoms that are often incorrectly managed. Along with palliative treatments that have been the standard of care, the recent approval of the first therapy for CAD has added to the toolbox of strategies that clinicians use to manage this disorder.

As part of the 2022 “Annual Rare Cancers and Blood Disorders Series,” join an esteemed hematology/oncology expert to review the symptoms and pathology of CAD to aid in a timelier diagnosis. This activity will explore the need to coordinate care with a multidisciplinary team and the integration of a new treatment option into patient care to ensure better outcomes for patients. Participating clinicians will also learn about investigational therapies in development to benefit patients living with CAD.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Apply clinical coordination strategies to decrease the time to diagnosis for patients with CAD
  • Anticipate physiological, psychological, and social impacts of CAD on patients
  • Review emerging clinical trial data and the mechanisms of action of new therapies

Post a comment to this article